Quality & safety

Octapharma has earned global recognition for the safety and quality of our products. We strive for the highest quality throughout the entire production process as shown below.

We strive for the highest quality throughout the entire production process.
This quality system serves one purpose: at any stage in this process, we can trace back the origin of a single donation of plasma included in the manufacturing process.

Selection of donation centres

  • Inspections by Octapharma and national and international regulatory authorities and health care agencies

  • GMP* compliant

*Good Manufacturing Practice 

Donor selection criteria

  • Health screening, medical questionnaire and blood test

  • Low risk for viral transmission

  • Absence of sexually transmitted diseases

Donation testing

Testing of each donation for:

  • Hepatitis A, B & C, HIV and Parvovirus B19, using a nucleic acid amplification test (NAT)

  • Three infectious disease markers: anti-HIV 1 & 2, anti-HCV and HBsAg

2. SDC

Single donation control

  • Registration of incoming plasma and control of documentation

  • Incoming plasma quarantined prior to approval for use in manufacturing

  • Nucleic acid amplification test (NAT) and testing of three viral markers (anti-HIV 1 and 2, anti-HCV and HBsAg) are performed for all plasma samples prior to shipment and results are verified during a single donation control step

  • Release of plasma for manufacturing

  • Performance of confirmatory testing of the plasma for manufacturing and for two viral markers (anti-HIV 1 and 2, HBsAg)

*Good Manufacturing Practice / † Good Laboratory Practice 


Fractionation, visual inspection and packing

Pooling of plasma

Fractionation and purification

Virus inactivation

  • Two or three independent, complementary and validated inactivation steps are taken to eliminate enveloped and non-enveloped viruses

End formulation

  • Sterile filling, visual inspection and packing

*Good Manufacturing Practice


Manufacturing process according to GMP*

  • Change control, supplier approvals, inspections, education, documentation, handling of deviations, qualification and validation etc.

Quality assurance and quality control

  • Strict incoming goods, in-process and final product quality controls

  • Environmental monitoring

*Good Manufacturing Practice 

Batch release

  • Batch quarantined until internal, national and international batch release


Distribution of finished products according to GDP*

*Good Distribution Practice 

Regulatory approval of products

In Canada, Health Canada is the federally regulated agency that evaluates the safety, efficacy and tolerability of each product in a particular indication from data obtained through a GCP clinical trial. This is required for the licensure of any product routine clinical use 

Drug Safety

  • Also known as Pharmacovigilance, it refers to the monitoring of all our products ensuring their continued safety. When we receive information about any individual safety event from any source, we collect detailed information, perform quality control for accuracy, code it, classify it and promptly report it Health Canada. Safety reports from Canada and also globally are compiled annually and submitted to Health Canada annually

  • Signal management

‡ Good Pharmacovigilance / § Good Clinical Practice


Pharmacovigilance involves:

  • Scheduling, preparation (including data evaluation and quality control), submission and assessment of periodic safety update reports

  • Continuous safety profile monitoring and benefit-risk evaluation of authorised medicinal products and notification of changes to authorities

  • Communicating information to patients and healthcare professionals about changes to the risk-benefit balance of products

  • Implementation of variations to marketing authorisations for safety reasons according to the urgency required